Skip to main content
SpringerLink
Log in

Mésothéliome pleural malin

  • Chapter
Thérapeutique du cancer

  • 757 Accesses

Résumé

Le mésothéliome pleural malin (MM) est une néoplasie primitive de la plèvre. C’est une tumeur rare (906 cas en France en 2005). Son incidence a augmenté entre 1980 et 1995 dans les deux sexes mais diminue actuellement chez l’homme et augmente de façon plus modérée chez la femme. Le rôle de l’amiante comme principal agent étiologique dans la survenue de cette néoplasie est acquis ; on retrouve une exposition à l’amiante dans 85 % des mésothéliomes pleuraux chez l’homme et dans 40 % chez la femme. La majorité de ces expositions est professionnelle.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Recommandations de la Société de Pneumologie de Langue Française sur le mésothéliome pleural (2006) Conférence d’experts — texte long. Rev Mal Respir 23: 11S7–11S103

    Google Scholar 

  2. British Thoracic Society Standards of Care Committee (2007) BTS statement on malignant mesothelioma in the UK 2007. Thorax 62(Suppl II): ii1–ii19

    Article  Google Scholar 

  3. Wagner JC, Slaggs CA, Marchand P (1960) Diffuse pleural mesothelioma and abestos exposure in the North Western Cape Province. Br J Ind Med 17: 260–271

    PubMed  CAS  Google Scholar 

  4. Expertise collective (1996) Effets sur la santé des principaux types d’exposition à l’amiante. éditions INSERM, Paris

    Google Scholar 

  5. Goldberg M, Imbernon E, Rolland P et al. (2006) The French National Mesothelioma Surveillance Program. Occup Environ Med 6: 390–395

    Article  Google Scholar 

  6. Witherby SM, Butnor KJ, Grunberg SM (2007) Malignant mesothelioma following thoracic radiotherapy for lung cancer. Lung Cancer 57: 410–413

    Article  PubMed  Google Scholar 

  7. Neugut I, Ashan H, Antman KH (1997) Incidence of malignant pleural mesothelioma after thoracic radiotherapy. Cancer 80: 948–950

    Article  PubMed  CAS  Google Scholar 

  8. Travis LB, Fossa SD, Schonfeld SJ et al. (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97: 1354–1365

    Article  PubMed  Google Scholar 

  9. Roushdy-Hammady I, Siegel J, Emri S et al. (2001) Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357: 444–445

    Article  PubMed  CAS  Google Scholar 

  10. Shivapurkar N, Wiethege T, Wistuba II et al. (1999) Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations. J Cell Biochem 76: 181–188

    Article  PubMed  CAS  Google Scholar 

  11. Jaurand MC, Levy F (1999) Effets cellulaires et moléculaires de l’amiante. Med Sci 15: 1370–1378

    Google Scholar 

  12. Robinson BWS, Lake RA (2005) Advances in malignant mesothelioma. N Engl J Med 353: 1591–1603

    Article  PubMed  CAS  Google Scholar 

  13. Zucali PA, Giaccone G (2006) Biology and management of malignant pleural mesothelioma. Eur J Cancer 42: 2706–2714

    Article  PubMed  CAS  Google Scholar 

  14. Lee AY, Raz DJ, He B, Jablons DM (2007)) Update on the molecular biology of malignant mesothelioma. Cancer 109: 1454–1461

    Article  PubMed  CAS  Google Scholar 

  15. Edwards JG, Swinson DEB, Jones JL et al. (2006) EGFR expression: associations with outcomes and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 54: 399–407

    Article  PubMed  CAS  Google Scholar 

  16. Destro A, Ceresoli GL, Falleni M et al. (2006) EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51: 207–215

    Article  PubMed  CAS  Google Scholar 

  17. Kothmaier H, Quenhenberger F, Halbwedl I et al. (2008) EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short-and long-term survivors. Thorax 63: 345–351

    Article  PubMed  CAS  Google Scholar 

  18. Recommandations de la Société de Pneumologie de Langue Française sur le mésothéliome pleural (2006) Conférence d’experts — texte court. Rev Mal Respir 23: 6S80–6S92

    Google Scholar 

  19. Galateau-Salle F, Brambilla E, Cagle P et al. (2006) Pathology of malignant mesothelioma: an update of the international mesothelioma panel. In: F GS, editor. Springer Verlag, London

    Chapter  Google Scholar 

  20. King JE, Thatcher N, Pickering CA, Hasleton PS (2006) Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using publishd data. Histopathology 48: 223–232

    Article  PubMed  CAS  Google Scholar 

  21. Robinson BW, Creany J, Lake R et al. (2003) Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362: 1612–1616

    Article  PubMed  CAS  Google Scholar 

  22. Scherpereel A, Grigoriu B, Conti M et al. (2006) Soluble mesothlin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173: 1155–1160

    Article  PubMed  CAS  Google Scholar 

  23. Pass HI, Dan Lott BS, Lonardo F et al. (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353: 1564–1573

    Article  PubMed  CAS  Google Scholar 

  24. Creaney J, Yeoman D, Demelker Y et al. (2008) Comparison of osteopontin, megakaryocyte potentiating facor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 3: 851–857

    Article  PubMed  Google Scholar 

  25. A proposed new international TNM staging system for malignant pleural mesothelioma (1995) From the International Mesothelioma interest group. Chest 108: 1122–1128

    Article  Google Scholar 

  26. Tsao AS, Wistuba I, Roth JA, Kindler HL (2009) Malignant pleural mesothelioma. J Clin Oncol 27: 2081–2090

    Article  PubMed  CAS  Google Scholar 

  27. Bard M, Debrosse D, Caliandro R et al. (2001) A plea for standardized thoracoscopy in malignant pleural mesothelioma. Rev Mal Respir 18(6 Pt 1): 585–589

    PubMed  CAS  Google Scholar 

  28. Rusch VW, Piantadosi S, Holmes EC (1991) The role of extrapleural pneumonectomy in malignant mesothelioma: a Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 102: 1–9

    PubMed  CAS  Google Scholar 

  29. Sugarbaker DJ, Garcia JP, Richards WG et al. (1996) Extrapleualr pneumonectomy in the multimodality therapy of malignant pleural mesothelioma: results in 120 consecutive patients. Ann Surg 224: 288–294

    Article  PubMed  CAS  Google Scholar 

  30. de Perrot M, Feld R, Cho BCG et al. (2009) Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27: 1413–1418

    Article  PubMed  Google Scholar 

  31. Erasmus JJ, Truong MT, Smythe WR et al. (2005) Integrated computed tomography-positron emission tomography in patients with potentially respectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovas Surg 129: 1364–1370

    Article  Google Scholar 

  32. Plathow C, Staab A, Schmaehl A et al. (2008) Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results. Invest Radiol 43(10): 737–744

    Article  PubMed  Google Scholar 

  33. Sterman DH, Kaiser LR, Albelda SM (1999) Advances in the treatment of malignant pleural mesothelioma. Chest 116: 504–520

    Article  PubMed  CAS  Google Scholar 

  34. Kristensen CA, Nottrup TJ, Berthelsen AK et al. (2009) Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. Radiother Oncol 92: 96–99

    Article  PubMed  Google Scholar 

  35. Boutin C, Rey F, Viallet JR (1995) Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 108: 754–758

    Article  PubMed  CAS  Google Scholar 

  36. O’Rourke N, Garcia JC, Paul J et al. (2007) A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiotherapy and Oncology 84: 18–22

    Article  PubMed  Google Scholar 

  37. Berghmans T, Bréchot J-M, Robinet G et al. (2006) Chimiothérapie du mésothéliome pleural malin. Recommandations de la Société de Pneumologie de Langue Française sur le mésothéliome pleural. Conférence d’experts. Rev Mal Respir 23: 11S57–11S70

    Article  PubMed  CAS  Google Scholar 

  38. Ellis P, Davies AM, Evans WK et al. (2004) The use of chemotherapy with advanced malignant pleural mesothelioma: Evidence Summary Report 7-14-1, October 12, www.cancercare.on.can

    Google Scholar 

  39. Berghmans T, Paesmans M, Lalami Y et al. (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38: 111–121

    Article  PubMed  CAS  Google Scholar 

  40. Berghmans T, Lafitte JJ, Mascaux C et al. (2003) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Cancer Therapy 1: 245–256

    Google Scholar 

  41. Byrne MJ, Nowak AK (2004) Modified RECIST criterii for assessment of response in malignant pleural mesothelioma. Ann Oncol 15: 257–260

    Article  PubMed  CAS  Google Scholar 

  42. Ceresoli GL, Chiti A, Zucali PA (2006) Early response evaluation in malignant pleural mesothelioma by positron emission tomoigraphy with [18F] fluorodeoxyglucose. J Clin Oncol 24: 4587–4593

    Article  PubMed  Google Scholar 

  43. Muers MF, Stephens RJ, Fisher P et al. (2008) Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01):a multicentre randomised trial. Lancet 371: 1685–1694

    Article  PubMed  CAS  Google Scholar 

  44. O’Brien ME, Watkins D, Ryan C et al. (2006) A randomised trial of malignant mesothelioma of early versus delayed chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 17: 270–275

    Article  PubMed  Google Scholar 

  45. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636–2644

    Article  PubMed  CAS  Google Scholar 

  46. Van Meerbeeck JP, Gaafar R, Manegold C et al. (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881–6889

    Article  PubMed  Google Scholar 

  47. Ceresoli GL, Zucali PA, Favaretto AG et al. (2006) Phse II of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24: 1443–448

    Article  PubMed  CAS  Google Scholar 

  48. Talbot DC, Margery J, Dabouis G et al. (2007) Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 25: 4751–4756

    Article  PubMed  CAS  Google Scholar 

  49. Govindan R, Kratzke RA, Herndon II JE et al. (2005) On behalf of the Cancer and Leukemia Group B. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11: 2300–2304

    Article  PubMed  CAS  Google Scholar 

  50. Garland LL, Rankin C, Gandara DR et al. (2007) Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group study. J Clin Oncol 25: 2406–2413

    Article  PubMed  CAS  Google Scholar 

  51. Karrison T, Kindler HL, Gandara DR et al. (2007) Final analysis of a multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with mesothelioma. J Clin Oncol (Proc ASCO) 25(18 S): 391S (abst 7526)

    Google Scholar 

  52. Janne PA, Wang XF, Krug LM et al. (2007) Sorafenib in malignant mesothelioma: a phase II trial of the Cancer and Leukemia Group B (CALGB 30307). J Clin Oncol (Proc ASCO) 25(18 S): 435S (abst 7707)

    Google Scholar 

  53. Buckstein R, Meyer RM, Seymour L et al. (2007) Phase II testing of sunitinib: the National Cancer Institute of Canada clinical trials group IND program trials IND.182-185. Curr Oncol 14: 154–161

    Article  PubMed  CAS  Google Scholar 

  54. Mathy A, Baas P, Dalesio O, van Zandwijk N (2005) Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 50: 83–86

    Article  PubMed  Google Scholar 

  55. Jackman D, Kindler HL, Fidias P et al. (2008) Erlotinib plus bevacizumab in previously treated patients with malignant mesothelioma. Cancer 113(4): 808–814

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut National du Cancer, 52, avenue André Morizet, 92100, Boulogne-Billancourt

    J.-M. Bréchot

Authors
  1. J.-M. Bréchot
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France

About this chapter

Cite this chapter

Bréchot, JM. (2011). Mésothéliome pleural malin. In: Thérapeutique du cancer. Springer, Paris. https://doi.org/10.1007/978-2-8178-0021-9_17

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0021-9_17

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0020-2

  • Online ISBN: 978-2-8178-0021-9

Publish with us

Policies and ethics

Search

Navigation